Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2011-05-31 Interim / Quarterly Rep…
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, XTL Biopharmaceuticals Ltd., with the SEC. It contains interim financial statements for the first quarter ended March 31, 2011, including a Board of Directors' report, reviewed condensed consolidated financial statements, and other regulatory disclosures. The content includes detailed financial data, analysis of operating results, liquidity, and financing resources for the quarter, which is characteristic of an Interim / Quarterly Report. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2011-05-31 English
ANNUAL REPORT
Annual Report FY 2010
2011-05-31 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It announces that XTL Biopharmaceuticals Ltd. has received Orphan-drug designation from the FDA for a drug treatment for Multiple Myeloma. The document is an immediate report announcing a regulatory milestone rather than a full financial report or detailed presentation. It does not contain financial statements or detailed management discussion. The length is 4882 characters, which is relatively short and consistent with an announcement. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2011-05-31 English
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer submitted to the SEC. It contains an announcement about the company's submission of an application to the FDA for Orphan Drug status for a specific drug. The document is relatively short (3785 characters) and primarily serves as a regulatory announcement rather than a detailed financial report or presentation. It does not contain financial statements, management discussion, or detailed analysis. It is not an annual or interim report, earnings release, or any other detailed financial filing. Given the nature of the content and the form type, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2011-04-21 English
Annual Report 2011
Annual Report Classification · 95% confidence The document is a Form 6-K filed with the SEC by XTL Biopharmaceuticals Ltd., a foreign private issuer. It contains detailed financial statements and additional information for the year ended December 31, 2010, including a description of the company's business, board of directors' report, consolidated financial statements, and internal control reports. The document is comprehensive and includes substantive financial data and analysis for a fiscal year, indicating it is a full annual report for a foreign private issuer. Form 6-K is used by foreign private issuers to furnish reports to the SEC, often including annual reports or other significant financial disclosures. Given the detailed financial statements and business description for the full fiscal year, this filing corresponds to an Annual Report (10-K equivalent for foreign issuers). Therefore, the appropriate classification is Annual Report (10-K).
2011-03-31 English
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, XTL Biopharmaceuticals Ltd., with the SEC. It reports a business update regarding the acquisition of technology and intellectual property from MinoGuard Ltd. The document includes details about the term sheet, the drug SAM-101, and clinical trial results. It does not contain comprehensive financial statements or detailed financial analysis typical of an annual or interim report. It is not a transcript, audit report, or other specific report type. The document is a regulatory filing providing material business information to the SEC and investors. Given the nature of Form 6-K filings as periodic reports of material events by foreign private issuers, and the absence of detailed financial data, the appropriate classification is Regulatory Filings (RNS).
2011-03-25 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.